Lantheus Holdings (LNTH) Cash from Financing Activities (2014 - 2026)
Lantheus Holdings' (LNTH) quarterly Cash from Financing Activities came in at -$11.6 million in Q1 2026, up 36.2% year-on-year from -$8.5 million in Q1 2025, and up 88.47% on a QoQ basis from -$100.8 million in Q4 2025.
Lantheus Holdings (LNTH) Cash from Financing Activities (2014 - 2026) Analysis & Trends
Lantheus Holdings (LNTH) has 13 years of Cash from Financing Activities data on file, last reported at -$11.6 million in Q1 2026.
- On a quarterly basis, Cash from Financing Activities rose 36.2% year-over-year to -$11.6 million in Q1 2026; TTM through Mar 2026 was -$310.0 million, a 158.52% decrease from a year earlier, with the FY2025 full-year figure at -$316.6 million, down 167.08% from the prior year.
- Cash from Financing Activities for Q1 2026 stood at -$11.6 million, up from -$100.8 million in the prior quarter.
- Over the last five years, Cash from Financing Activities for LNTH reached as high as $317.8 million in Q4 2022 and fell as low as -$103.7 million in Q4 2024.
- Historically, Cash from Financing Activities has averaged -$8.7 million across 5 years, with a median of -$4.1 million in 2023.
- Across the five-year window, Cash from Financing Activities jumped 15235.24% in 2022 and tumbled 99507.07% in 2025, its largest moves.
- Year by year, Cash from Financing Activities stood at $317.8 million in 2022, then sank by 100.14% to -$450000.0 in 2023, then plunged by 22935.33% to -$103.7 million in 2024, then climbed by 2.77% to -$100.8 million in 2025, then soared by 88.47% to -$11.6 million in 2026.
- Per Business Quant data, the three most recent Cash from Financing Activities figures were -$11.6 million in Q1 2026, -$100.8 million in Q4 2025, and -$99.2 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 13.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | -840.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -494.13 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | -1.48 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | -203.80 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | -86.10 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | -65.00 Mn |
| 10 | Lantheus Holdings | 6.72 Bn | 6.22 Bn | 230.92 Mn | -11.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -11.62 Mn |
| Mar 31, 2026 | -11.62 Mn |
| Dec 31, 2025 | -100.79 Mn |
| Dec 31, 2025 | -100.79 Mn |
| Sep 30, 2025 | -99.17 Mn |
| Sep 30, 2025 | -99.17 Mn |
| Jun 30, 2025 | -98.41 Mn |
| Jun 30, 2025 | -98.41 Mn |
| Mar 31, 2025 | -18.22 Mn |
| Mar 31, 2025 | -18.22 Mn |
| Dec 31, 2024 | -103.66 Mn |
| Dec 31, 2024 | -103.66 Mn |
| Sep 30, 2024 | 1.87 Mn |
| Sep 30, 2024 | 1.87 Mn |
| Jun 30, 2024 | 99,000.00 |
| Jun 30, 2024 | 99,000.00 |
| Mar 31, 2024 | -16.85 Mn |
| Mar 31, 2024 | -16.85 Mn |
| Dec 31, 2023 | -450,000.00 |
| Dec 31, 2023 | -450,000.00 |